Winnie Seto

Winnie Seto

Auto-generated profile, based on publicly available information

Winnie Seto

Department of Pharmacy The Hospital for Sick Children Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2017 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
PDF file
ELElaine Lau
Elaine Lau
JBJason Brophy
Jason Brophy
LSLindy Samson
Lindy Samson
FKFatima Kakkar
Fatima Kakkar
DCDouglas M Campbell
Douglas M Campbell
ABAri Bitnun
Ari Bitnun
Background: Nevirapine (NVP)-based combination antiretroviral therapy is routinely prescribed to infants deemed at high risk of vertical HIV infection in our centers. We evaluated NVP pharmacokinetics and safety of this regimen. Methods: Neonates were recruited prospectively between September 2012 and April 2015 or enrolled retrospectively if treated similarly before prospective study initiation. NVP was dosed at 150 mg/m2 daily for 14 days, then twice daily for 14 days. NVP levels were drawn at weeks 1, 2, and 4 [target trough (NVP-T): 3–8 mg/L]. Results: Thirty-three neonates were included (23 prospectively). Median gestational age (GA) and birth weight were 38 weeks (32–41 weeks) and 2.9 kg (1.5–4.2 kg), respectively. Median NVP-Ts were 8.2 mg/L (1.6–25.1 mg/L), 3.5 mg/L (1.6–6.8 mg/L), and 4.3 mg/L (0.1–19.9 mg/L) at weeks 1, 2, and 4, respectively. The proportions with therapeutic NVP-T were 42%, 61%, and 73% at these same timepoints. Median apparent oral clearance (CL/F) increased from 0.05 L·kg−1·h−1 (0.01–0.50 L·kg−1·h−1) at week 2 to 0.18 L·kg−1·h−1 (0.01–0.78 L·kg−1·h−1) at week 4. Increased drug exposure [area under the curve (AUCτ)] correlated with younger GA (r = 0.459, P = 0.032) and lower birth weight (r = 0.542, P = 0.009). The most common adverse events potentially attributable to combination antiretroviral therapy were transient asymptomatic hyperlactatemia (26%), anemia (24.7%), and neutropenia (22.1%). Conclusions: Treatment dose NVP was generally well-tolerated and associated with normalization of trough levels over time in most cases without dose adjustment. Lower empiric dosing is recommended for infants <34 weeks of GA. Routine therapeutic drug monitoring may not be required for infants ≥34 weeks of GA.

28 August 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
ECErin Chung
Erin Chung
WSWinnie Seto
Winnie Seto
Introduction: Vancomycin dosing tailored for newborns is challenging due to the significant influence of maturation and organ function on pharmacokinetics. Population pharmacokinetic (popPK) models can be used to improve target attainment in neonates. Objectives: The primary objective was to derive and evaluate a popPK model of intravenous vancomycin for neonates. Second, the predictive performance of this popPK model was compared with published popPK models. Methods: This is a retrospective cohort study of neonates admitted to the neonatal intensive care unit receiving intravenous vancomycin. A popPK model was derived with 70% of the dataset using a nonlinear mixed effects modeling method. The predictive performance of the current popPK model was validated and compared with 22 published popPK models using the remaining 30% of the dataset. Monte Carlo simulations (MCS) were performed to derive optimal dosing regimens to treat neonatal sepsis caused by coagulase‐negative staphylococci (CoNS). Results: Among 655 vancomycin courses from 448 neonates, 78% of vancomycin trough concentrations were outside target range (10–15 mg/L) for central nervous system infections and 43% were outside target range (5–12 mg/L) for other infections using the institution's vancomycin dosing. A one‐compartment model best described the observed data with a mean clearance of 0.11 ± 0.03 L/kg/h and volume of distribution (V) of 1.02 ± 0.08 L/kg. Body weight (WT), postmenstrual age (PMA), and serum creatinine (SCr) were significant covariates associated with clearance ( p < 0.001) and body WT was a significant covariate associated with V ( p = 0.009). Our study's popPK model has similar or better accuracy and precision than other published models. MCS‐derived vancomycin doses from the validated model achieved >90% target attainment for a steady state through target range of 10–15 mg/L in the majority of PMA and SCr categories (78%) to treat CoNS sepsis. Conclusion: A vancomycin dosing guideline derived from a validated popPK model in neonates with CoNS sepsis is recommended to improve target attainment.

14 December 2010 in The Canadian Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
WSWinnie T W Seto
Winnie T W Seto
TBTeresa Bishara
Teresa Bishara
ATAngela Trope
Angela Trope
CPChris Parshuram
Chris Parshuram
Use of Milrinone in Critically Ill Children

18 November 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
TLTerrence Lo
Terrence Lo
HKHan Byul Kang
Han Byul Kang
CMCarol McNair
Carol McNair
DWDiane Wilson
Diane Wilson
JBJennifer Bizzarri
Jennifer Bizzarri
ECErin Chung
Erin Chung
Objectives: Recently, dexmedetomidine has replaced opioids for sedation in neonatal intensive care unit (NICU) patients with hypoxic–ischemic encephalopathy (HIE). The study objectives were to describe dosing patterns, evaluate compliance, and compare effectiveness and safety between the original (pre‐implementation) and revised (post‐implementation) in‐house dexmedetomidine dosing guidelines. Study Design: This was a retrospective cohort study that included neonates with HIE admitted to a level IV NICU for therapeutic hypothermia comparing two dexmedetomidine dosing regimens: (1) pre‐implementation: starting dose of 0.05 μg/kg/h followed by titration by 0.05 μg/kg/h every 6 h as needed, and (2) post‐implementation: 0.2 μg/kg/h followed by titration by 0.1 μg/kg/h every 30–60 min as needed. Results: A total of 106 neonates were included: 50 in the pre‐implementation group and 56 in the post‐implementation group. Compliance to post‐implementation formulary recommendations was 69.6% for initial doses, 62.5% for dose increases, and 44.6% for dose decreases. An increased odds of opioid exposure (adjusted odds ratio: 7.13, 95% confidence interval (CI): 1.59–51.5, p = 0.02) and greater proportion of bradycardia (21.4% vs. 4%, p = 0.03) were observed in the post‐implementation group. No significant differences in effectiveness end points or hypotension were observed between groups ( p ≥ 0.05). Conclusion: Compliance with formulary‐recommended dexmedetomidine dosing was variable and dose decreases were common in the post‐implementation group. The post‐implementation dosing approach was not associated with improved effectiveness outcomes (sedation) but was associated with greater opioid exposure and more bradycardia, supporting the need for further prospective evaluation to determine the optimal dexmedetomidine dosing in neonates undergoing HIE.